2对一商务服务,小辣椒3电影免费播放,姐妹牙医电影观看免费高清

聚戊糖多硫醇

NMR下載 COA and HPLC MSDS下載
names：
Pentosan Polysulfate
CAS號：
37300-21-3
MDL Number： No data available
MF(分子式)： C 10 H 18 O 21 S 4 MW(分子量)： 4000-6000
EINECS:No data available Reaxys Number:No data available
Pubchem ID:37720 Brand:BIOFOUNT

聚戊糖多硫醇(37300-21-3,Pentosan Polysulfate)是一種半合成的多硫酸木聚糖，是一種具有類肝素特性的硫酸戊糖基多糖。戊聚糖多硫酸鹽是一種口服生物可利用的半合成藥物，具有抗炎和促成軟骨生成的特性。戊聚糖是一種有效且選擇性的抗艾滋病毒藥物。聚戊糖多硫醇是細胞膜通透性抑制劑。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000639-200mg	200mg	>98.0%	￥ 0.00	￥ 0.00		Backorder	- +	￥ 0.00
YZM000639-100mg	100mg	>98.0%	￥ 858.00	￥ 858.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	聚戊糖多硫醇(37300-21-3),戊聚糖多硫酸鈉,戊聚糖多硫酸鹽,[(2R,3R,4S,5R)-2-羥基-5-[(2S,3R,4S,5R)-5-羥基-3,4-二磺基氧基四氫吡喃-2-基]氧基-3-磺基氧基四氫吡喃-4-基]氫硫酸鹽;
英文別名	Pentosan Polysulfate(37300-21-3);4-O-(2,3-Di-O-sulfo-β-D-xylopyranosyl)-2,3-di-O-sulfo-β-D-xylopyr anose;
CAS號	37300-21-3
Inchi	InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1
InchiKey	FCCNSUIJIOOXEZ-SJYYZXOBSA-N
分子式 Formula	C 10 H 18 O 21 S 4
分子量 Molecular Weight	4000-6000
溶解度Solubility	生物體外In Vitro:DMSO溶解度< 1 mg/mL(insoluble or slightly soluble)H2O< 0.1 mg/mL(insoluble)
性狀	固體粉末,Power
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

聚戊糖多硫醇(37300-21-3,Pentosan Polysulfate)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：聚戊糖多硫醇試劑,聚戊糖多硫醇雜質,聚戊糖多硫醇中間體,聚戊糖多硫醇密度,聚戊糖多硫醇合成,聚戊糖多硫醇溶解度,聚戊糖多硫醇旋光度,聚戊糖多硫醇閃點,聚戊糖多硫醇結構式,聚戊糖多硫醇購買,

產品說明	聚戊糖多硫醇(37300-21-3,Pentosan Polysulfate)是一種有效的口服生物可利用的半合成藥物，具有抗炎和促軟骨生成的特性
Introduction	聚戊糖多硫醇(37300-21-3,Pentosan Polysulfate)is an orally bioavailable medication with antinflammatory and prohondrogenic properties. Pentosan Polysulfate also is a potent and selective antiIVagent.
Application1	Pentosan Polysulfate is used for the treatment of ?interstitial cystitis.
Application2	聚戊糖多硫醇是細胞膜通透性抑制劑。
Application3

聚戊糖多硫醇(37300-21-3,Pentosan Polysulfate)藥理學：
聚戊糖多硫醇是一種低分子量的肝素樣化合物。它具有抗凝血和纖溶作用。聚戊糖多硫醇是半合成的肝素樣葡糖胺聚糖。盡管其作用機理尚不清楚，但戊聚戊糖多硫醇可通過防止刺激性溶質到達被其包裹的細胞來控制細胞的通透性。經口服施用，排泄的聚戊糖多硫醇粘附在膀胱壁上，防止刺激物進入膀胱細胞以及間質性膀胱炎（IC）的發展或進展，這是一些化學療法的并發癥。該試劑還具有抗凝血和纖溶特性。聚戊糖多硫醇是抗凝劑，防止血液凝結的代理。聚戊糖多硫醇是木糖硫酸氫鹽的聚合物，每個碳水化合物單體包含兩個硫酸鹽基團。它結合成纖維細胞生長因子（FGFs）以及其他肝素結合生長因子。已經顯示它也與FGFR-1 的肝素結合位點相互作用。聚戊糖多硫醇抑制轉染了FGF-4的SW13腎上腺皮質細胞的生長以及轉染了FGF-1或FGF-4的MCF-7乳腺癌細胞的致瘤性。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Schuchman EH, et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One. 2013;8(1):e54459.

Baba M, et al. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res. 1988 Sep;9(6):335-43.

Wu J, et al. Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice. Lab Invest. 2011 Oct;91(10):1459-71.

聚戊糖多硫醇(37300-21-3,Pentosan Polysulfate)參考文獻：

1，戊聚糖鈉和硫酸鈣多硫酸鹽的抗凝和抗血栓形成作用的實驗研究。
Giedroj? J;Radziwon P;Klimiuk M;Bielawiec M;Breddin HK;K?oczko J J Physiol Pharmacol. 1999 Mar;50(1):111-9.
In the present study we have compared the antithrombotic and anticoagulant properties of sodium and calcium derivatives of pentosan polysulphate (Na-PPS, Ca-PPS). The antithrombotic effect of these agents have been investigated in an experimental thrombosis model in which rat mesenteric venules diameter of 20-30 microm were injured by well defined Argon laser lesions. Furthermore, the in vivo and in vitro anticoagulant activities (aPTT, Heptest) of these agents have been studied. Thrombus formation was significantly inhibited after s.c. injection of Na-PPS and Ca-PPS in doses above 10 mg/kg. The duration of the antithrombotic effect lasted 8 h for Na-PPS and 12 h for Ca-PPS. After oral administration of Na-PPS an antithrombotic effect was not observed. Oral application of Ca-PPS in doses higher than 20 mg/kg significantly inhibited thrombus formation. Na-PPS and Ca-PPS markedly prolonged clotting time in aPTT and Heptest in concentrations ranging from 0.01 to 0.2 mg/ml rat PTT. Two h after s.c. administration of these agents in a dose 10 mg/kg, the aPTT increased 3-fold and Heptest 2.5-fold compared to controls. After oral application of 50 mg/kg Na-PPS and Ca-PPS no effect on coagulation test could be measured.

2.硫酸化多糖的細胞表面受體：巨噬細胞亞群的潛在標志物。
Chong AS;Parish CR Immunology. 1986 Jun;58(2):277-84.
The expression of a diverse array of receptors for sulphated polysaccharides on lymphocytes has been demonstrated by Parish & Snowden (1985). This paper presents evidence to suggest that other cell types, namely macrophages, polymorphonuclear leucocytes, mast cells and fibroblasts, can bind similar polysaccharides. Using a rosetting assay and eleven structurally unique polysaccharides, each cell type was observed to bind a characteristic array of these polysaccharides. Analysis of the polysaccharide reactivity of macrophages revealed that BCG-activated and thioglycollate-elicited macrophages express an expanded repertoire of reactivity compared to resident peritoneal macrophages. For example, only thioglycollate-elicited macrophages, but not resident and BCG-activated peritoneal macrophages, reacted with the glycosaminoglycans, chondroitin-4-sulphate, chondroitin-6-sulphate and dermatan sulphate, while both BCG- and thioglycolate-activated, but not resident peritoneal macrophages, bound pentosan polysulphate-coupled sheep erythrocytes. The expression of the receptors for chondroitin-4 and -6-sulphate was observed to be cyclic and peaked at 2 and 5-6 days after thioglycollate treatment.

3.評論文章：放射直腸疾病的當前治療選擇
Hong JJ;Park W;Ehrenpreis ED Aliment Pharmacol Ther. 2001 Sep;15(9):1253-62.
Radiation proctopathy is a common unfortunate complication following radiation therapy of pelvic malignancies. Symptoms of chronic radiation proctopathy include haematochezia, urgency, constipation, tenesmus, diarrhoea and rectal pain. Currently, a wide variety of pharmacological options, endoscopic cautery techniques and surgical procedures have been proposed for the treatment of chronic radiation proctopathy. Although these have been proposed primarily as treatment for rectal bleeding, the control of other symptoms has been noted with some of these agents. Pharmacological options include 5-aminosalicylic acid preparations, coticosteroid enemas, sucralfate (oral, enemas), formalin, short chain fatty acid enemas, oestrogen/progesterone, hyperbaric oxygen, antioxidants, sodium pentosan polysulphate and misoprostol rectal suppositories. Of these, sucralfate and formalin therapy appear to be effective for bleeding control. Misoprostol rectal suppositories and oral sucralfate may be useful in the prevention of acute and chronic symptoms of radiation proctopathy. Endoscopic cautery techniques have included the use of Nd:YAG laser and argon laser for coagulation of bleeding neovascular telangiectasias.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開